Browsing Tag
Cerevel Therapeutics
3 posts
MapLight Therapeutics prices $250m Nasdaq IPO at $17 a share as biotech listings rebound
Find out how MapLight Therapeutics’ $250 million Nasdaq IPO is reigniting biotech investor sentiment and funding its next wave of CNS drug trials.
AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will…
Cerevel launches phase 3 Parkinson’s disease clinical trials for tavapadon
Parkinson’s disease clinical trials : Cerevel Therapeutics, a US biopharma company, has initiated a phase 3 clinical trial…